Martin Kaiser

Professor of Haematology

The Institute of Cancer Research & The Royal Marsden NHS Foundation Trust

United Kingdom

Research Interests

Explore related searches

Professors in United Kingdom Professors in Immunology Immunology professors in United Kingdom

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Martin Kaiser is a Professor of Haematology at The Institute of Cancer Research/Royal Marsden Hospital in the UK. His research focuses on multiple myeloma, including clinical characteristics, treatment outcomes, and the genetic underpinnings of the disease. He has authored recent articles addressing topics such as clonal evolution, immunoparesis, and the efficacy of various treatments for multiple myeloma.

Articles (10)

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Collaborators (7)

Charles Agbuduwe

University College London

UNITED KINGDOM

View details

Kwee Yong

University College London

UNITED KINGDOM

View details

Brian Walker

Indiana State University

UNITED STATES

View details

Gulnaz Iqbal

Associate Professor

University of Warwick

UNITED KINGDOM

View details

Holger Auner

Full Professor (Professeur ordinaire)

University of Lausanne

SWITZERLAND

View details

Suvi Savola

Head of Oncogenetics

MRC-Holland

NETHERLANDS

View details

Francesco Maura

Assistant Professor

Sylvester Comprehensive Cancer Center

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Martin Kaiser

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Impact of Etiological Cytogenetic Abnormalities on the Depth of Immunoparesis and Survival in Newly Diagnosed Multiple Myeloma

Clinical characteristics and outcomes of IgD myeloma: experience across UK national trials

Ixazomib with cyclophosphamide and dexamethasone in relapsed or refractory myeloma: MUKeight phase II randomised controlled trial results

Redefining nonmeasurable multiple myeloma using mass spectrometry

Positive selection as the unifying force for clonal evolution in multiple myeloma

Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma

Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life

A real‐world study of panobinostat, weekly bortezomib and dexamethasone in a very heavily pretreated population of multiple‐myeloma patients

High-Throughput Molecular Cancer Cell Line Characterization Using Digital Multiplex Ligation-Dependent Probe Amplification for Improved Standardization of in Vitro Research

An enhanced genetic model of relapsed IGH-translocated multiple myeloma evolutionary dynamics

Collaborators (7)

Charles Agbuduwe

Kwee Yong

Brian Walker

Gulnaz Iqbal

Holger Auner

Suvi Savola

Francesco Maura

Make your next move.